X4 PHARMACEUTICALS, INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $2.00K.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $8.81M.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $40.00K, a 58.33% decline year-over-year.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $29.00K, a 27.50% decline year-over-year.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2021 was $40.00K, a 68.50% decline from fiscal 2020.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2020 was $127.00K, a 63.19% decline from fiscal 2019.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2019 was $345.00K, a 4828.57% increase from fiscal 2018.
- X4 PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2018 was $7.00K, a 22.22% decline from fiscal 2017.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-09-30 | $2.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $8.81M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $40.00K 10-K · filed 2024-03-21 | |
| 2021-03-31 | $40.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $127.00K 10-K · filed 2023-03-21 | |
| 2020-09-30 | $29.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $2.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $96.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $345.00K 10-K · filed 2022-03-17 | |
| 2019-09-30 | $40.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $5.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $113.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $7.00K 10-K · filed 2021-03-19 | |
| 2018-06-30 | $7.00K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $9.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |